Hims & Hers Health (NYSE:HIMS – Get Free Report) and biote (NASDAQ:BTMD – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Risk and Volatility
Hims & Hers Health has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500. Comparatively, biote has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500.
Insider and Institutional Ownership
63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by company insiders. Comparatively, 32.4% of biote shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Hims & Hers Health | $2.35 billion | 3.07 | $128.37 million | ($0.63) | -48.99 |
| biote | $192.22 million | 0.21 | $27.05 million | $0.11 | 10.45 |
Hims & Hers Health has higher revenue and earnings than biote. Hims & Hers Health is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations for Hims & Hers Health and biote, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Hims & Hers Health | 1 | 12 | 3 | 0 | 2.12 |
| biote | 1 | 1 | 1 | 1 | 2.50 |
Hims & Hers Health currently has a consensus price target of $32.43, indicating a potential upside of 5.08%. biote has a consensus price target of $2.50, indicating a potential upside of 117.39%. Given biote’s stronger consensus rating and higher possible upside, analysts plainly believe biote is more favorable than Hims & Hers Health.
Profitability
This table compares Hims & Hers Health and biote’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Hims & Hers Health | -5.51% | -6.51% | -1.20% |
| biote | 3.19% | -22.33% | 12.10% |
Summary
biote beats Hims & Hers Health on 8 of the 15 factors compared between the two stocks.
About Hims & Hers Health
Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
